Lead Product(s): GC027
Therapeutic Area: Oncology
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2020
GC027 is the first product candidate developed using TruUCARâ„¢ to treat relapsed or refractory (R/R) T-cell malignancies.